Biotech News

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

TG Therapeutics (TGTX)TG TherapeuticsEarnings

Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million Third-quarter 2026 total global revenue of approximately $260

Related news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

Stock data

Close
64.88 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States